Jacob Chacko - 02 Jan 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 17:41:01 UTC
Previous filing
17 Dec 2024
Next filing
20 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Award $0 +600,000 $0.000000 600,000 02 Jan 2025 Common Stock 600,000 $8.26 Direct F1
transaction ORIC Restricted Stock Unit Award $0 +100,000 $0.000000 100,000 02 Jan 2025 Common Stock 100,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.